President Trump is considering support for groups in Iran willing to take up arms against the regime, U.S. officials told the Wall Street Journal, a move that could position Iranian factions as ground ...

Gold Spot US Dollar, S&P 500, Gold Futures, Crude Oil WTI Futures. Read 's Market Analysis on Investing.com India ...

At 04:25 ET (09:25 GMT), the Dollar Index, which tracks the greenback against a basket of six other currencies, traded 0.8% higher to 99.080, trading at its highest level since January after rising ...

Investing.com - The conflict in the Middle East has disrupted financial markets, and the turmoil has made clear that the U.S.

Robust fourth-quarter data center sales, both sequentially and year over year, was notable given Nvidia’s scale. “We’d call out FQ1’27 sales guidance ($78B) in particular as being the highlight of the ...

The following is the complete interview with Upbound Group CEO Fahmi Karam. Reporter: You’ve described Brigit as the cornerstone of your digital transformation. How does a traditional "rent-to-own" ...

The company achieved a significant milestone by delivering average net cash of £16.8m for the period, compared to net debt of £37.6m in the prior year. Period-end net cash stood at £102.9m, up ...

Investing.com -- HSBC has taken a more bullish stance on Block after Q4 2025 results, with analyst Saul Martinez sharply raising earnings estimates and lifting the bank’s target price to $77 from $70, ...

Investing.com -- eHealth, Inc. (NASDAQ:EHTH) shares jumped 17% in pre-open trading Tuesday after Chief Executive Officer Derrick A. Duke purchased 187,969 shares of the company’s common stock at $1.38 ...

Services prices jumped from 3.6% year-on-year in January to 4.2% in February. Wage costs and home rents have been ...

Investing.com -- InfuSystem Holdings, Inc (NYSE:INFU) shares rose 1% in early trading Tuesday following the disclosure that Barry G. Steele, the company’s Executive Vice President and CFO, purchased ...

Investing.com -- Shares of uniQure (NASDAQ:QURE) fell 12.86% to $9.15 in premarket trading on Tuesday after the U.S. Food and Drug Administration rejected the company’s trial data for its Huntington’s ...